• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    5/7/25 1:39:49 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCCC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    C4 Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    12529R107

    (CUSIP Number)


    04/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    WASATCH ADVISORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,754,534.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,473,332.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,473,332.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    C4 Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    490 ARSENAL WAY, SUITE 120, WATERTOWN, MASSACHUSETTS, 02472
    Item 2. 
    (a)Name of person filing:

    Wasatch Advisors LP
    (b)Address or principal business office or, if none, residence:

    505 Wakara Way, 3rd Floor, Salt Lake City, 84108, United States
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    12529R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    7,473,332
    (b)Percent of class:

    10.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    6,754,534

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    7,473,332

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WASATCH ADVISORS LP
     
    Signature:Mike Yeates
    Name/Title:CEO
    Date:05/07/2025
    Get the next $CCCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCCC

    DatePrice TargetRatingAnalyst
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$4.00Equal-Weight
    Stephens
    1/29/2024$6.00Underweight → Neutral
    JP Morgan
    12/13/2023$2.00 → $12.00Hold → Buy
    Stifel
    2/24/2023$12.00 → $10.00Underperform → Neutral
    Credit Suisse
    2/24/2023$15.00 → $5.00Neutral → Underweight
    JP Morgan
    11/4/2022$22.00 → $15.00Overweight → Neutral
    JP Morgan
    10/11/2022$6.00Underweight
    Morgan Stanley
    More analyst ratings

    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Grogan Donna Roy was granted 9,581 shares, increasing direct ownership by 29% to 42,280 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      4/3/25 4:11:53 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Anderson Kenneth Carl was granted 7,841 shares, increasing direct ownership by 7% to 127,609 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      4/3/25 4:11:41 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Hirsch Andrew covered exercise/tax liability with 22,217 shares and was granted 223,500 shares, increasing direct ownership by 91% to 423,145 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      2/18/25 4:55:35 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 Portfolio Decision to Prioritize Cemsidomide Development; C4T to Seek Partnership Opportunities to Advance BRAF Program CFT8919 Phase 1 Trial Continues to Advance in Partnership with Be

      5/7/25 7:00:00 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended

      2/27/25 7:00:00 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics to Participate in Upcoming March Investor Conferences

      WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the Events & Presentations page of the company's website. The archived replay of the webcast will be available for approximately 30 days following the live event. Leerink Partners Global Healthcare Conference: Management will participate in the confer

      2/24/25 7:00:00 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • C4 Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded C4 Therapeutics from Equal Weight to Overweight and set a new price target of $12.00 from $8.00 previously

      12/19/24 7:32:29 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stephens initiated coverage on C4 Therapeutics with a new price target

      Stephens initiated coverage of C4 Therapeutics with a rating of Equal-Weight and set a new price target of $4.00

      11/18/24 8:38:35 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded C4 Therapeutics from Underweight to Neutral and set a new price target of $6.00

      1/29/24 7:07:29 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    Financials

    Live finance-specific insights

    See more
    • C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

      – Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co

      4/8/22 1:00:00 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

      - Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr

      3/8/22 4:30:00 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    Leadership Updates

    Live Leadership Updates

    See more
    • C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended

      2/27/25 7:00:00 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

      In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated a 38 Percent ORR and 19 Percent Complete Metabolic Response (CMR) Rate Across All Subtypes; In Peripheral T-Cell Lymphoma (PTCL), Cemsidomide Achieved a 44 Percent ORR and 25 Perc

      12/8/24 12:30:00 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

      Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. "Our commitment to assembling a group of industry experts who offer diverse perspectives to our Board has resulted in bringing on some of the industry's brightest minds

      11/20/24 7:00:00 AM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

      SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

      11/14/24 7:53:04 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by C4 Therapeutics Inc.

      SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

      11/14/24 6:43:36 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

      SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

      11/14/24 4:05:17 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CCCC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

      SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

      5/15/25 8:09:15 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

      SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

      5/15/25 4:52:29 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

      SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

      5/7/25 1:39:49 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care